Earlier in the day, the stock witnessed a gap down start to the session. The stock quoted a 52-week high price of Rs 978.4 and a 52-week low of Rs 503.4 on NSE. Around 13563 shares changed hands on the counter till 12:40PM (IST).
The stock opened at Rs 552.0 and has touched an intraday high and low of Rs 557.75 and Rs 549.3 during the session so far. The counter quoted a price-to-earnings (PE) ratio of 12.21, earnings per share (EPS) of Rs 45.2 and price to book value (PB) of 1.59, while the return on equity (ROE) stood at Rs 10.77.
Promoter/ FII Holding
The promoters held 51.83 per cent stake in the company as of July 15, while FII and MF ownerships stood at 22.48 per cent and 10.09 per cent, respectively.
With a market capitalisation of Rs 32340.88 crore, the company operates in the Pharma – Indian industry. For the quarter ended 31-Mar-2022, the company reported consolidated sales of Rs 5858.25 crore, down 3.44 per cent from the previous quarter?s Rs 6067.21 crore and down 3.64 per cent from the same quarter a year ago. The company reported net profit of Rs 576.46 crore for the latest quarter, down 28.08 per cent from the corresponding quarter last year.
The relative strength index (RSI) of the stock stands at 56.42. The RSI oscillates between zero and 100. Traditionally, it is considered overbought condition when the RSI value is above 70 and oversold condition when it is below 30. Analysts say the RSI indicator should not be seen in isolation, as it may not be sufficient to take a trading call, just the way a fundamental analyst cannot give a “buy” or “sell” recommendation using a single valuation ratio.